Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Company Reports
Aquestive Therapeutics
Aquestive Therapeutics
(AQST)
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
*Currency in USD
Company Revenue
Quarterly
Quarterly
Annual
Annual
Projections
*Quarterly sales USD (in millions)
Mock data
Subscribe for the real data
Revenue by Drug
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name
Drug Name
Approved
Patent Expires
Indication
Exservan
Riluzole
2019-11-22
2024-2029
Amyotrophic lateral sclerosis
Zuplenz
Ondansetron
2010-07-02
2029-2030
Alcoholism
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
Riluzole
amyotrophic lateral sclerosis
,
motor neuron disease
,
sclerosis
Diazepam
epilepsy
Ondansetron
postoperative nausea and vomiting
,
neoplasms
,
vomiting
,
nausea
,
diarrhea
,
emergencies
,
dehydration
,
gastroenteritis
Benzodiazepine
neoplasms
,
psoriasis
,
breast neoplasms
,
multiple myeloma
,
plasma cell neoplasms
,
malaria
,
leukemia
,
myeloid leukemia acute
,
myeloid leukemia
,
seizures
,
complex partial epilepsy
,
healthy volunteers/patients
Antineoplaston a10
lymphoma
,
leukemia
,
bcr-abl positive chronic myelogenous leukemia
,
myeloid leukemia
,
blast crisis
,
carcinoma
,
breast neoplasms
,
pancreatic neoplasms
,
neoplasms
,
head and neck neoplasms
,
lung neoplasms
,
sarcoma
,
bile duct neoplasms
,
liver neoplasms
,
colonic neoplasms
,
squamous cell carcinoma
,
squamous cell neoplasms
,
chordoma
,
t-cell lymphoma
,
t-cell lymphoma peripheral
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use